Mattingly Q. Cardiovascular diseases: World Health Organisation; 2023 https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1. Accessed 7 Nov 2023.

Google Scholar 

Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2017. Eur Heart J. 2017;(7):508–79.

Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019. JACC. 2020;(25):2982–3021.

Luengo-Fernandez R, Walli-Attaei M, Gray A, Torbica A, Maggioni AP, Huculeci R, et al. Economic burden of cardiovascular diseases in the European Union: a population-based cost study. Eur Heart J. 2023;(0):1–16.

Andersson C, Johnson AD, Benjamin EJ, Levy D, Vasan RS. 70-year legacy of the Framingham Heart Study. Nat Rev Cardiol. 2019;(11):687–98.

Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G, et al. Autoimmune diseases and cardiovascular risk: A population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet. 2022;(10354):733–43.

Wallace ZS, Fu X, Harkness T, Stone JH, Yuqing CH. All-cause and cause-specific mortality in ANCA-associated vasculitis: Overall and according to ANCA type. Rheumatol. 2020;(9):2308–15.

Kitching AR, Anders H-J, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020;(1):1–27.

Rasmussen N, Wiik A, Jayne DR. A historical essay on detection of anti-neutrophil cytoplasmic antibodies. Nephrol Dial Transplant. 2015;(Supplement 1):i8–i13.

Mahr A, Katsahian S, Varet H, Guillevin L, Hagen EC, Höglund P, et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: A cluster analysis. Ann Rheum Dis. 2013;(6):1003–10.

Emmi G, Bettiol A, Gelain E, Bajema IM, Berti A, Burns S, et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023;(6):378–93.

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;(9):1583–94.

Walton EW. Giant-cell granuloma of the respiratory tract (Wegener’s granulomatosis). Br Med J. 1958;(5091):265–70.

Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Hoglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K, the European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;(3):488–94.

Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, et al. Damage in the ANCA-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;(1):177–84.

Vegting Y, Vogt L, Anders HJ, de Winther MPJ, Bemelman FJ, Hilhorst ML. Monocytes and macrophages in ANCA-associated vasculitis. Autoimmun Rev. 2021;(10):102911.

Van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol. 2009;(2):195–204.

Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;(1):56.

Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: Testing and clinical relevance. Circulation. 2007;(10):1285–95.

Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;(344):852–4.

Farrah TE, Melville V, Czopek A, Fok H, Bruce L, Mills NL, et al. Arterial stiffness, endothelial dysfunction and impaired fibrinolysis are pathogenic mechanisms contributing to cardiovascular risk in ANCA-associated vasculitis. Kidney Int. 2022;(5):1115–26.

Lijnen HR, Collen D. Impaired fibrinolysis and the risk for coronary heart disease. Circulation. 1996;(9):2052–4.

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;(32):2459–72.

Wallace ZS, Fu X, Liao K, Kallenberg CGM, Langford CA, Merkel PA, et al. Disease activity, antineutrophil cytoplasmic antibody type, and lipid levels in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2019;(11):1879–87.

Farrah TE, Anand A, Gallacher PJ, Kimmitt R, Carter E, Dear JW, et al. Endothelin receptor antagonism improves lipid profiles and lowers PCSK9 (proprotein convertase subtilisin/kexin type 9) in patients with chronic kidney disease. Hypertension. 2019;(2):323–30.

Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C. Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun. 2008;(2):341–4.

Ross R. Atherosclerosis--An inflammatory disease. N Engl J Med. 1999;(2):115–26.

DRW J, Merkel PA, Schall TJ, Bekker P, Group AS. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;(7):599–609.

Thurman JM, Yapa R. Complement therapeutics in autoimmune disease. Front Immunol. 2019;(10):672.

Speidl WS, Exner M, Amighi J, Kastl SP, Zorn G, Maurer G, et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J. 2005;(21):2294–9.

Rua-Figueroa I, Arencibia-Mireles O, Elvira M, Erausquin C, Ojeda S, Francisco F, et al. Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: A 2-year longitudinal study. Ann Rheum Dis. 2010;(6):1136–9.

Tedesco F, Fischetti F, Pausa M, Dobrina A, Sim RB, Daha MR. Complement-endothelial cell interactions: Pathophysiological implications. Mol Immunol. 1999;(4-5):261–8.

de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. Ann Intern Med. 2009;(10):670–80.

De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;(8):2461–9.

Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;(7):2180–8.

Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;(3):211–20.

Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;(3):221–32.

Walsh M, Merkel PA, Peh CA, Szpirt WM, Puechal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;(7):622–31.

Massicotte-Azarniouch D, Petrcich W, Walsh M, Canney M, Hundemer GL, Milman N, et al. Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: A population-based cohort study. Clin Kidney J. 2022;(4):681–92.

Berti A, Matteson EL, Crowson CS, Specks U, Cornec D. Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: A 20-year population-based cohort study. Mayo Clin Proc. 2018;(5):597–606.

Nygaard L, Polcwiartek C, Nelveg-Kristensen KE, Carlson N, Kristensen S, Torp-Pedersen C, et al. Increased risk of cardiovascular disease preceding diagnosis of incident ANCA-associated vasculitis: A Danish nationwide study. Rheumatology (Oxford). 2023;(kead377):1–9.

Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023;(0):1–18.

Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;(10):764–70.

Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts AC, Leufkens HG, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;(8):859–65.

Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007;(5):545–59.

Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. PLoS Med. 2020;(12):e1003432.

Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Höglund P, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: Long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015;(3):471–81.

Exley AR, Carruthers DM, Luqmani RA, Kitas GD, Gordon C, Janssen BA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM. 1997;(6):391–9.

Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: A randomized clinical trial. JAMA. 2021;(21):2178–87.

Smith MR. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene. 2003;(47):7359–68.

Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 2010;(8):1579–87.

Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guérin C, et al. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med. 2013;(10):1273–80.

Kridin K, Mruwat N, Ludwig RJ. Association of rituximab with risk of long-term cardiovascular and metabolic outcomes in patients with pemphigus. JAMA Dermatol. 2023;(1):56–61.

Kim DG, Lee J, Seo WJ, Lee JG, Kim BS, Kim MS, et al. Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation: A propensity-matched study. Sci Rep. 2019;(1):16475.

Hsue PY, Scherzer R, Grunfeld C, Imboden J, Wu Y, Del Puerto G, et al. Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. J Am Heart Assoc 2014;(5):e001267.

Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation. 2004;(25):3122–31.

Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor. Blood. 1986;(5):1114–8.

Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;(1):36–44.

Walsh M, Faurschou M, Berden A, Flossmann O, Bajema I, Hoglund P, et al. Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2014;(9):1571–6.

Walsh M, Casian A, Flossmann O, Westman K, Hoglund P, Pusey C, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;(2):397–402.

Sachais BS, Shaz BH. Apheresis to mitigate atherosclerotic vascular disease. Am J Hypertens. 2018;(8):945–9.

Walsh M, Collister D, Zeng L, Merkel PA, Guyatt G, Peh CA, Szpirt W, Ito-Hara T, Jayne DJ. The effects of plasma exchange in patients with ANCA-associated vasculitis: An updated systematic review and meta-analysis. Br Med J. 2022;(376):e064604.

Smith RM, Jones RB, Specks U, Bond S, Nodale M, Al-Jayyousi R, et al. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: An international randomised controlled trial. Ann Rheum Dis. 2023;(7):937–44.

Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;(12):2083–9.

Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: A randomised, non-inferiority trial. Ann Rheum Dis. 2019;(3):399–405.

Taylor EB, Ryan MJ. Immunosuppression with mycophenolate mofetil attenuates hypertension in an experimental model of autoimmune disease. J Am Heart Assoc. 2017;(3):e005394.

Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol. 2006;(12 Suppl 3):S218–25.

van Leuven SI, Kastelein JJ, Allison AC, Hayden MR, Stroes ES. Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles? Cardiovasc Res. 2006;(2):341–7.

van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ, Wade NS, Gabriel CL, Kastelein JJ, et al. Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice. Ann Rheum Dis. 2012;(3):408–14.

Raza K, Thambyrajah J, Townend JN, Exley AR, Hortas C, Filer A, et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: Lessons for atherosclerotic disease? Circulation. 2000;(13):1470–2.

Booth AD, Wallace S, McEniery CM, Yasmin BJ, Jayne DR, et al. Inflammation and arterial stiffness in systemic vasculitis: A model of vascular inflammation. Arthritis Rheum. 2004;(2):581–8.

Lind L, Berglund L, Larsson A, Sundström J. Endothelial function in resistance and conduit arteries and 5-year risk of cardiovascular disease. Circulation. 2011;(14):1545–51.

Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: The Rotterdam Study. Circulation. 2006;(5):657–63.

Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;(6):768–79.

Terrier B, Chironi G, Pagnoux C, Cohen P, Puechal X, Simon A, et al. Factors associated with major cardiovascular events in patients with systemic necrotizing vasculitides: Results of a longterm followup study. J Rheumatol. 2014;(4):723–9.

Bramlage CP, Kroplin J, Wallbach M, Minguet J, Smith KH, Luders S, et al. Management of cardiovascular risk factors in patients with ANCA-associated vasculitis. J Eval Clin Pract. 2017;(4):747–54.

Iudici M, Fasano S, Gabriele Falcone L, Pantano I, La Montagna G, Migliaresi S, et al. Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: A long-term retrospective cohort study. Rheumatology (Oxford). 2016;(9):1623–30.

Iacono D, Fasano S, Pantano I, D'Abrosca V, Ruscitti P, Margiotta DPE, et al. Low-dose aspirin as primary prophylaxis for cardiovascular events in rheumatoid arthritis: An Italian multicentre retrospective study. Cardiol Res Pract. 2019:(2019):1–7.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;(21):2195–207.

Xie W, Huang H, Xiao S, Yang X, Zhang Z. Effect of statin use on cardiovascular events and all-cause mortality in immune-mediated inflammatory diseases: A systematic review and meta-analysis involving 148,722 participants. Pharmacol Res. 2020:(160):1–10.

Miller-Hodges E, Anand A, Shah ASV, Chapman AR, Gallacher P, Lee KK, et al. High-sensitivity cardiac troponin and the risk stratification of patients with renal impairment presenting with suspected acute coronary syndrome. Circulation. 2018;(5):425–35.

Welsh P, Preiss D, Hayward C, Shah ASV, McAllister D, Briggs A, et al. Cardiac troponin T and troponin I in the general population. Circulation. 2019;(24):2754–64.

Investigators S-H, Newby DE, Adamson PD, Berry C, Boon NA, Dweck MR, et al. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med. 2018;(10):924–33.

Tzolos E, Williams MC, McElhinney P, Lin A, Grodecki K, Flores Tomasino G, et al. Pericoronary adipose tissue attenuation, low-attenuation plaque burden, and 5-year risk of myocardial infarction. JACC Cardiovasc Imaging. 2022;(6):1078–88.

ClinicalTrials.gov. Multicenter, prospective, randomized, controlled, double-blind trial on the impact of rosuvastatin on subclinical markers of atherosclerosis in patients with primary necrotizing vasculitides (STATVAS) (2022). https://classic.clinicaltrials.gov/ct2/show/NCT02117453. Accessed 7 Nov 2023.

ClinicalTrials.gov. ETA and AT1 antagonism in ANCA-vasculitis (SPARVASC) (SPARVASC) (2023). https://classic.clinicaltrials.gov/ct2/show/NCT05630612. Accessed 7 Nov 2023.